Article
Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.
Pigment cell & melanoma research - 1 Jul 2018
Wongchenko Matthew J, Ribas Antoni, Dréno Brigitte, Ascierto Paolo A, McArthur Grant A, Gallo Jorge D, Rooney Isabelle A, Hsu Jessie, Koeppen Hartmut, Yan Yibing, Larkin James
Abstract excerpt
The prognostic significance of programmed death ligand-1 (PD-L1) on treatment outcomes in patients receiving BRAF with or without MEK inhibitors is not well understood. This retrospective exploratory analysis evaluated the association of tumour PD-L1 expression with progression-free survival (PFS) and overall survival (OS) among 210 patients in the coBRIM trial treated with cobimetinib plus vemurafenib or placebo...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.